Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CLYBL antisense RNA 2 (CLYBL-AS2) is a long non-coding RNA gene transcribed in the antisense direction relative to the CLYBL protein-coding gene. As an antisense lncRNA, it is expected to be involved in the regulation of gene expression through RNA-RNA or RNA-DNA interactions, but its specific biological function and physiological roles remain unclear. No direct association with human disease or actionable therapeutic targeting is reported. There are no known drugs, clinical indications, or biomarker uses for CLYBL-AS2, and it is not classified as an enzyme, receptor, transporter, or other classical drug target[1][4][6][9]. Notes: - CLYBL, a neighboring protein-coding gene, is a mitochondrial enzyme with malate synthase and β-methylmalate synthase activity[7], but CLYBL-AS2 is non-coding and unrelated to these enzymatic functions. - As with many antisense RNAs, CLYBL-AS2 may modulate the expression of its sense counterpart, but there is no published functional evidence or disease association at this time[1][4][6]. - No errors, misspellings, or spurious information were encountered for this target name.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CLYBL antisense RNA 2 (CLYBL-AS2).